Boehringer Ingelheim Initiates Long-term Study of Nerandomilast in Pulmonary Fibrosis Patients
A follow-up study is underway to evaluate the long-term tolerance and efficacy of nerandomilast in patients with pulmonary fibrosis.
Company
Pharmaceutical intelligence for Boehringer Ingelheim with 10 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.